• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23734 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. NICE interventional procedures guidance 794
2024     National Institute for Health and Care Excellence (NICE) Digital technologies for assessing attention deficit hyperactivity disorder (ADHD). NICE diagnostics guidance 60
2024     National Institute for Health and Care Excellence (NICE) Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices. NICE diagnostics guidance 61
2024     National Institute for Health and Care Excellence (NICE) Belzutifan for treating tumours associated with von Hippel-Lindau disease. NICE technology appraisal guidance 1011
2024     National Institute for Health and Care Excellence (NICE) Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia. NICE technology appraisal guidance 1013
2024     National Institute for Health and Care Excellence (NICE) Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1010
2024     National Institute for Health and Care Excellence (NICE) Avapritinib for treating advanced systemic mastocytosis. NICE technology appraisal guidance 1012
2024     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024     National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024     National Institute for Health and Care Excellence (NICE) Elafibranor for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1016
2024     National Institute for Health and Care Excellence (NICE) Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over. NICE technology appraisal guidance 1019
2024     National Institute for Health and Care Excellence (NICE) Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024     National Institute for Health and Care Excellence (NICE) Eplontersen for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 1020
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: adjustment of antidepressants for the follow-up of a major depressive disorder or an anxiety disorder]
2024     Haute Autorite de sante (HAS) [Management missing teeth with implant-supported prostheses (complete edentulism or single missing teeth)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of placental growth factor (PlGF) testing in suspected preeclampsia]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: support for the implementation of a pilot project on the targeted use of medications for the treatment of obesity in designated centers]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evaluation of the lung cancer screening pilot project - effects on participants' health and organizational impact on the healthcare system]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Vosoritide in achondroplasia]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Partially hydrolyzed formula to prevent cow’s milk allergy]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Indications for urinary catheterization in sedated patients
2024     Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: access to innovations in health and social services - financing and decision-making]
2024     NIHR Health Technology Assessment programme Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
2024     Norwegian Medical Products Agency (NOMA) [Interferon gamma-1b for treatment of Friedreich’s ataxia: a health technology assessment without submitted documentation]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: prolotherapy's efficacy and safety in the treatment of chronic musculoskeletal pain]
2024     Health Sciences Institute in Aragon (IACS) [Portable external trigeminal nerve stimulator (eTNS) device for the treatment of migraine headaches]
2024     NIHR Health and Social Care Delivery Program The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2024     NIHR Health and Social Care Delivery Program Challenges and guidance for implementing social distancing for COVID-19 in care homes: a mixed methods rapid review
2024     NIHR Health and Social Care Delivery Program Understanding and improving the quality of primary care for people in prison: a mixed-methods study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood quantification of fludarabine by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)]
2024     Norwegian Institute of Public Health (NIPH) [Robot–assisted hysterectomy for benign conditions: A rapid health technology assessment]
2024     NIHR Health and Social Care Delivery Program Pathways to specialist community perinatal mental health services: a two-site longitudinal retrospective service evaluation
2024     NIHR Health and Social Care Delivery Program What happens between first symptoms and first acute exacerbation of COPD – observational study of routine data and patient survey
2024     NIHR Health Services and Delivery Research programme Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     NIHR Health and Social Care Delivery Program Using the Recommended Summary Plan for Emergency Care and Treatment in Primary Care: a mixed methods study
2024     NIHR Health and Social Care Delivery Program Implementing an artificial intelligence command centre in the NHS: a mixed-methods study
2024     NIHR Health Technology Assessment programme Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis
2024     NIHR Health Technology Assessment programme Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT
2024     NIHR Health Technology Assessment programme Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     NIHR Health Technology Assessment programme Behavioural interventions to treat anxiety in adults with autism and moderate to severe intellectual disabilities: the BEAMS-ID feasibility study
2024     NIHR Health Technology Assessment programme Timing of Stoma Closure in Neonates: the ToSCiN mixed-methods study
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     NIHR Health Technology Assessment programme Interventions for people with perceptual disorders after stroke: the PIONEER scoping review, Cochrane systematic review and priority setting project
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: gene panel for the identification of inborn errors of immunity - evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update and assessment regional programs. Methylmalonic acidemias; Propionic acidaemia]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood quantification of ruxolitinib by high-performance liquid chromatographytandem mass spectrometry (HPLC-MS/MS)]
2024     WorkSafeBC Effectiveness of extra corporeal shockwave therapy (ESWT) in treating costochondritis and soft tissue contusion: 2024 update
2024     WorkSafeBC Effectiveness of platelet rich plasma therapy (PRP) in treating shoulder labral tears
2024     WorkSafeBC Effectiveness of extra corporeal shockwave therapy (ESWT) in treating shoulder labral tears
2024     WorkSafeBC Efficacy/effectiveness of Cryoderm Cooling Gel®/Ligament Restore Supplement in treating lumbar sprain/strain
2024     WorkSafeBC Causal association between soft tissue injury/trauma and aggravation of CRPS
2024     WorkSafeBC Causal association between firefighting and pulmonary fibrosis
2024     WorkSafeBC Effectiveness of prolotherapy in shoulder labral tears
2024     WorkSafeBC Efficacy/effectiveness of brain mapping in treating concussions
2024     WorkSafeBC Causal association on the development of trigeminal neuralgia post covid-19 vaccine
2024     WorkSafeBC Causal association in developing breast cancer among female firefighters
2024     WorkSafeBC Efficacy/effectiveness of prolotherapy in treating wrist sprain/strain or repetitive strain injury (RSI)
2024     Haute Autorite de sante (HAS) [Targeted next generation sequencing gene panel in the medical management of chronic lymphocytic leukemia]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: determination of blood titanium levels]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice : close follow-up practices for people at risk of suicide after hospital discharge: challenges and possible solutions]
2024     NIHR Health Technology Assessment programme Strategies for older people living in care homes to prevent urinary tract infection: the StOP UTI realist synthesis
2024     Haute Autorite de sante (HAS) [Next generation sequencing gene panel for gastrointestinal stromal tumour care]
2024     Haute Autorite de sante (HAS) [Evaluation of high-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids]
2024     NIHR Health and Social Care Delivery Program Effects of computerised clinical decision support systems (CDSS) on nursing and allied health professional performance and patient outcomes: a systematic review of experimental and observational studies
2024     NIHR Health and Social Care Delivery Program Health and wellbeing of survivors of sexual violence and abuse attending sexual assault referral centres in England: the MESARCH mixed-methods evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cataract: Does surgery with the femtosecond laser offer advantages over other procedures for people affected?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Generalized anxiety disorder - Do apps help people affected cope with their condition?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofersen (SOD1-associated amyotrophic lateral sclerosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cefepime/enmetazobactam (bacterial infections, several therapeutic indications) – Assessment according to §35a (para. 1c) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – 2nd Addendum to Project A24-13]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, treatment-naive patients) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Danicopan (paroxysmal haemoglobinuria) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (high-grade malignant glioma in paediatric patients aged 1 year and older, in combination with trametinib) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib and trametinib (malignant glioma with BRAF V600E mutation in children aged 1 year and older) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria); assessment according to §35a Social Code Book (SGB) V; estimation of patient numbers]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gozetotide (positron emission tomography, prostate cancer [mCRPC]) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fruquintinib (colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, adjuvant) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (unresectable or metastatic urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Addendum to Project A24-15]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – Addendum to Project A24-13]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third addendum to Commission A21-131]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Quality indicators for the care and services provided in long-term left ventricular assist device implantation programs]